(Q37259573)

19 August 2017

1 reference

title

Telomerase as a universal tumor antigen for cancer vaccines (English)

1 reference

19 August 2017

Gregory L Beatty

1

1 reference

19 August 2017

Robert H Vonderheide

series ordinal

2

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

881-887

1 reference

Cancer vaccines based on the identification of genes encoding cancer regression antigens

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

T cell defined tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Tumor-specific shared antigenic peptides recognized by human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Decreased tumor surveillance in perforin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Model predicting survival in stage I melanoma based on tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase as a universal tumor-associated antigen for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Prospects and challenges of building a cancer vaccine targeting telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Universal tumor antigens as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Human telomerase and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase activation, cellular immortalization and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase: a target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Switching and signaling at the telomere

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomeres shorten during ageing of human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomere reduction in human colorectal carcinoma and with ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase catalytic subunit homologs from fission yeast and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Extension of life-span by introduction of telomerase into normal human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Creation of human tumour cells with defined genetic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Inhibition of telomerase limits the growth of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Cytotoxic T cell immunity against telomerase reverse transcriptase in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

The immunogenicity of the hTERT540-548 peptide in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase immunity from bench to bedside: round one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.881

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.881

1 reference

19 August 2017

1 reference